|Minimum Order Quantity||1 Box|
|Packaging Size||30 Tablets|
|Usage||Personal, Clinical, Hospital|
|Minimum Order Quantity||5 Bottle|
|Drug Name||Tenofovir Alafenamide|
|Minimum Order Quantity||3 Bottle|
|Pack size||30 Tablets per bottle|
|Manufacturer||Emcure Pharmaceuticals Ltd.|
|Composition||dolutegravir,lamivudine and tenofovir disoproxil fumarate|
|Packaging Size||1 x 28|
We are offering Daclahep Tablets to our client. Daclatasvir 60mg (brand names, Natdac, Myekhla, Daclawin ,Dacihep) is a nucleotide analog used in combination with other drugs for the treatment of Hepatitis C virus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir- daclatasvir based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of HCV.
|Packaging Size||1 x 30 Tabs|
|Composition||Bictegravir (50mg),Emtricitabine (200mg),and Tenofovir Alafenamide (25mg)|
Bictegravir/emtricitabine/tenofovir alafenamide (brand name Biktarvy, TAFFIC) is a fixed dose combination drug for the treatment of HIV-1 infection. It contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.
Biktarvy is an example of a combination drug that can be taken as a complete regimen for treatment of the human immunodeficiency virus.
Combination therapy for HIV, often called highly active antiretroviral therapy (HAART), is composed of two or more types of antiretroviral drugs. Combination therapy decreases the likelihood that drug resistance will occur, because it is unlikely that the HIV-1 strains will be able to mutate enough to become resistant to all drugs being used in the combination.